Citigroup
CLDX icon

Citigroup’s Celldex Therapeutics CLDX Stock Holding History

Citigroup’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,600
Closed -$1.04M – 5850
2024
Q3 		$1.04M Buy
+30,600
New +$1.17M ﹤0.01% 3236
2023
Q1 		– Sell
-10,000
Closed -$446K – 5541
2022
Q4 		$446K Hold
10,000
– – ﹤0.01% 3252
2022
Q3 		$281K Sell
10,000
-110,000
-92% -$3.37M ﹤0.01% 3592
2022
Q2 		$3.23M Sell
120,000
-60,000
-33% -$1.74M ﹤0.01% 1779
2022
Q1 		$6.13M Hold
180,000
– – ﹤0.01% 1564
2021
Q4 		$6.96M Buy
+180,000
New +$7.84M ﹤0.01% 1616
2019
Q4 		– Sell
-4,700
Closed -$10K – 7677
2019
Q3 		$10K Sell
4,700
-318
-6% -$736 ﹤0.01% 7056
2019
Q2 		$13K Buy
+5,018
New +$17K ﹤0.01% 7222
2018
Q3 		– Sell
-927
Closed -$7K – 7751
2018
Q2 		$7K Sell
927
-880
-49% -$11.8K ﹤0.01% 7270
2018
Q1 		$63K Sell
1,807
-140
-7% -$5.42K ﹤0.01% 5990
2017
Q4 		$83K Sell
1,947
-1,166
-37% -$49.9K ﹤0.01% 5804
2017
Q3 		$134K Buy
3,113
+1,766
+131% +$66.2K ﹤0.01% 5317
2017
Q2 		$50K Buy
1,347
+614
+84% +$27.2K ﹤0.01% 5790
2017
Q1 		$40K Sell
733
-507
-41% -$26.4K ﹤0.01% 5851
2016
Q4 		$66K Buy
1,240
+353
+40% +$20.1K ﹤0.01% 6007
2016
Q3 		$54K Sell
887
-1,120
-56% -$69.7K ﹤0.01% 5615
2016
Q2 		$132K Sell
2,007
-1,660
-45% -$105K ﹤0.01% 4849
2016
Q1 		$208K Buy
3,667
+774
+27% +$87.1K ﹤0.01% 5054
2015
Q4 		$681K Buy
2,893
+1,220
+73% +$266K ﹤0.01% 3540
2015
Q3 		$265K Buy
1,673
+653
+64% +$185K ﹤0.01% 4285
2015
Q2 		$386K Buy
+1,020
New +$405K ﹤0.01% 3943

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's CLDX Position: Q2 2026 in Review

Citigroup increased its Celldex Therapeutics (CLDX) stake by 86% in Q2 2026, buying an estimated $6.05M and bringing the position to 404,703 shares worth $15.1M. The position accounts for 0.01% of the portfolio, ranked #1336.

Citigroup first reported a position in CLDX in Q2 2013 and has held it in 47 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Citigroup held 404,703 shares of Celldex Therapeutics worth $15.1M as of Q2 2026.
  • Citigroup bought 187,368 Celldex Therapeutics shares in Q2 2026, an estimated $6.05M.
  • Celldex Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1336 holding.
  • Citigroup first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.